AMLX - CIK 0001658551
Amylyx Pharmaceuticals, Inc. (AMLX) reported revenue of $0.00 for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $0.00 | -100.0% |
| FY 2024 | $87.37M | -77.1% |
| FY 2023 | $380.79M | +1612.9% |
| FY 2022 | $22.23M | +7700.0% |
| FY 2021 | $285.00K | - |
Amylyx Pharmaceuticals, Inc. (AMLX) reported revenue of $0.00 for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2021 and fiscal 2025, Amylyx Pharmaceuticals, Inc.'s revenue declined from $285.00K to $0.00.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.